Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
17.70
+1.07 (6.40%)
At close: Apr 24, 2026, 4:00 PM EDT
17.35
-0.34 (-1.95%)
After-hours: Apr 24, 2026, 7:44 PM EDT
Cue Biopharma Employees
Cue Biopharma had 29 employees as of December 31, 2025. The number of employees decreased by 12 or -29.27% compared to the previous year.
Employees
29
Change (1Y)
-12
Growth (1Y)
-29.27%
Revenue / Employee
$947,103
Profits / Employee
-$917,310
Market Cap
57.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 29 | -12 | -29.27% | 29 | 0 |
| Dec 31, 2024 | 41 | -12 | -22.64% | 41 | 0 |
| Dec 31, 2023 | 53 | 1 | 1.92% | 53 | 0 |
| Dec 31, 2022 | 52 | -7 | -11.86% | 51 | 1 |
| Dec 31, 2021 | 59 | 7 | 13.46% | 57 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Acrivon Therapeutics | 76 |
| ImmuCell | 73 |
| OnKure Therapeutics | 45 |
| iBio, Inc. | 20 |
| Edesa Biotech | 17 |
| ImageneBio | 15 |
| Cingulate | 14 |
CUE News
- 2 days ago - Cue Biopharma Announces 1-for-30 Reverse Stock Split - GlobeNewsWire
- 14 days ago - Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim - Benzinga
- 16 days ago - Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement - GlobeNewsWire
- 4 weeks ago - Cue Biopharma Announces CEO Transition - GlobeNewsWire
- 4 weeks ago - Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 - GlobeNewsWire
- 5 weeks ago - Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 weeks ago - Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases - GlobeNewsWire